Compare Bristol-Myers Squibb Co (BMY) vs Dollar Tree, Inc. (DLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Dollar Tree, Inc. — how do they compare? Bristol-Myers Squibb Co trades at $63.75 (market cap $129.94B), while Dollar Tree, Inc. trades at $128.69 (market cap $24.61B). The key difference: Bristol-Myers Squibb Co is far larger — about 5.3× Dollar Tree, Inc.'s market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Dollar Tree, Inc. pays none. Which is the better fit depends on your goals.
| BMY | DLTR | |
|---|---|---|
Market Cap | $129.94B | $24.61B |
Sector | Health | Health |
52-Week High | $65.89 | $141.21 |
52-Week Low | $42.60 | $85.04 |
Enterprise Value | $163.92B | $31.20B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Dollar Tree (DLTR) trades at $128.76, down 0.47% on the day. The stock exhibits a bullish technical trend, trading near its pivot point of $128 with support at $127. Fundamentally, the company reported a net loss of -$3.03B for 2025 despite strong operating cash flow of $2.86B. Recent news highlights a $2.5 billion share repurchase authorization announced on July 2, 2026 (Business Wire).
The outlook is mixed. Analyst consensus is a 'Buy' with a $126.69 price target, but significant risks exist from recent profitability challenges and competitive pressures. The share repurchase program may support EPS, but investors should weigh the negative net income against improving operational cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →
